Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical …

cell transplantation
autograft
  • 30 views
  • 07 Nov, 2020
  • 15 locations
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

should result in an even higher rate of deep (negative for MRD in conjunction with at least very good partial response [VGPR] as defined by the International Myeloma Working Group [IMWG]) with these

  • 8 views
  • 03 Mar, 2021
  • 58 locations
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Myeloma patients who relapse after prior treatment with bortezomib and lenalidomide have survival of less than 1 year. Recently, a randomized study of Pomalidomide and dexamethasone conducted in

maintenance therapy
neutrophil count
induction therapy
hysterectomy
bortezomib
  • 33 views
  • 21 Jan, 2021
  • 3 locations
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

  • 18 views
  • 17 Jun, 2021
  • 221 locations
Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy

1. Scientific background In patients with multiple myeloma high-dose chemotherapy followed by autologous stemcell transplantation is preferred to conventional therapy, since the

melphalan
remission
high dose chemotherapy
dexamethasone
  • 5 views
  • 07 Nov, 2020
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

The study is designed as a randomized, controlled, open-label, assessor blind, multicenter superiority trial with three parallel groups, and primary endpoint of immunophenotypic complete responses at 18 months after randomization. Block randomization will be performed with a 1:1:1 allocation ratio. Patients will be randomized up front to 3 arms. Patients …

  • 12 views
  • 24 Mar, 2021
  • 89 locations
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma

The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved the outcome for patients with multiple myeloma (MM) over the past 10 years. However

proteasome inhibitor
bortezomib
lenalidomide
remission
daratumumab
  • 0 views
  • 23 Jan, 2021
  • 1 location
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction Follow by Dara Consolidation

The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo. Nevertheless, until now four

  • 0 views
  • 22 Jan, 2021
  • 1 location
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival

smoldering myeloma
bone marrow procedure
lenalidomide
bone marrow plasma cells
dexamethasone
  • 12 views
  • 16 Jun, 2021
  • 62 locations
Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma

This is a randomized, controlled, open-label, Phase 3 multicenter study which will enroll patients that have Relapsed Refractory Multiple Myeloma and are double refractory to an Immunomodulatory

refractory multiple myeloma
melphalan
dexamethasone
progressive disease
  • 0 views
  • 02 Jun, 2021
  • 32 locations